Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 3.16
CLSN's Cash to Debt is ranked lower than
67% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. CLSN: 3.16 )
Ranked among companies with meaningful Cash to Debt only.
CLSN' s Cash to Debt Range Over the Past 10 Years
Min: 0.45  Med: 27.61 Max: No Debt
Current: 3.16
Equity to Asset 0.38
CLSN's Equity to Asset is ranked lower than
79% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CLSN: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
CLSN' s Equity to Asset Range Over the Past 10 Years
Min: -1.05  Med: 0.57 Max: 0.97
Current: 0.38
-1.05
0.97
F-Score: 3
Z-Score: -7.94
M-Score: -3.46
WACC vs ROIC
15.16%
-276.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3821.80
CLSN's Operating margin (%) is ranked lower than
87% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. CLSN: -3821.80 )
Ranked among companies with meaningful Operating margin (%) only.
CLSN' s Operating margin (%) Range Over the Past 10 Years
Min: -4943  Med: -2116.58 Max: -75.43
Current: -3821.8
-4943
-75.43
Net-margin (%) -4005.60
CLSN's Net-margin (%) is ranked lower than
88% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. CLSN: -4005.60 )
Ranked among companies with meaningful Net-margin (%) only.
CLSN' s Net-margin (%) Range Over the Past 10 Years
Min: -5098.8  Med: -1405.68 Max: -67.41
Current: -4005.6
-5098.8
-67.41
ROE (%) -94.12
CLSN's ROE (%) is ranked lower than
79% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. CLSN: -94.12 )
Ranked among companies with meaningful ROE (%) only.
CLSN' s ROE (%) Range Over the Past 10 Years
Min: -6771.43  Med: -93.27 Max: 257.55
Current: -94.12
-6771.43
257.55
ROA (%) -40.06
CLSN's ROA (%) is ranked lower than
61% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. CLSN: -40.06 )
Ranked among companies with meaningful ROA (%) only.
CLSN' s ROA (%) Range Over the Past 10 Years
Min: -217.17  Med: -44.46 Max: 121.96
Current: -40.06
-217.17
121.96
ROC (Joel Greenblatt) (%) -2241.03
CLSN's ROC (Joel Greenblatt) (%) is ranked lower than
71% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. CLSN: -2241.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLSN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4101.97  Med: -1418.77 Max: -115.63
Current: -2241.03
-4101.97
-115.63
EBITDA Growth (3Y)(%) -34.40
CLSN's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CLSN: -34.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLSN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.6  Med: -4.3 Max: 39.1
Current: -34.4
-57.6
39.1
EPS Growth (3Y)(%) -33.10
CLSN's EPS Growth (3Y)(%) is ranked lower than
82% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. CLSN: -33.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLSN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.2  Med: -6 Max: 33.9
Current: -33.1
-48.2
33.9
» CLSN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CLSN Guru Trades in Q3 2015

Jim Simons Sold Out
Chuck Royce 167,379 sh (-21.48%)
» More
Q4 2015

CLSN Guru Trades in Q4 2015

Jim Simons 25,648 sh (New)
Chuck Royce Sold Out
» More
Q1 2016

CLSN Guru Trades in Q1 2016

Jim Simons 27,648 sh (+7.80%)
» More
Q2 2016

CLSN Guru Trades in Q2 2016

Jim Simons 51,848 sh (+87.53%)
» More
» Details

Insider Trades

Latest Guru Trades with CLSN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:PTGEF, OTCPK:BNHLF, OTCPK:ONCYF, NAS:ONCS, NAS:ICCC, OTCPK:LVCLY, OTCPK:XBIO, NAS:AEZS, NAS:VTGN, NAS:PZRX, NAS:VICL, OTCPK:PPGNY, OTCPK:ANTB, NAS:ORPN, NAS:CLBS, NAS:BIOD, OTCPK:CLCS, NAS:CUR, OTCPK:QBIO, AMEX:MSTX » details
Traded in other countries:CBOB.Germany,
Celsion Corp is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies.

Celsion Corp was founded in 1982 and is a Delaware corporation. The Company is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's product include ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). The Company's pipeline also includes GEN-1 a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence. It is also working to develop and commercialize oncology therapies based on its technologies by developing novel therapeutics for cancer treatment. The Company faces competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The Company is subject to the periodic inspection of its clinical trials, facilities, procedures and operations and/or the testing of its products by the FDA to determine whether its systems and processes are in compliance with FDA regulations. The Company's research and development activities, pre-clinical tests and clinical trials, and ultimately the manufacturing, marketing and labeling of its products, are all subject to regulation by the FDA and foreign regulatory agencies.

Ratios

vs
industry
vs
history
P/B 1.92
CLSN's P/B is ranked higher than
77% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. CLSN: 1.92 )
Ranked among companies with meaningful P/B only.
CLSN' s P/B Range Over the Past 10 Years
Min: 1.25  Med: 2.15 Max: 167.59
Current: 1.92
1.25
167.59
P/S 58.10
CLSN's P/S is ranked lower than
79% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. CLSN: 58.10 )
Ranked among companies with meaningful P/S only.
CLSN' s P/S Range Over the Past 10 Years
Min: 2.23  Med: 20.55 Max: 585.38
Current: 58.1
2.23
585.38
Current Ratio 1.44
CLSN's Current Ratio is ranked lower than
83% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. CLSN: 1.44 )
Ranked among companies with meaningful Current Ratio only.
CLSN' s Current Ratio Range Over the Past 10 Years
Min: 0.3  Med: 4.44 Max: 104.65
Current: 1.44
0.3
104.65
Quick Ratio 1.44
CLSN's Quick Ratio is ranked lower than
79% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. CLSN: 1.44 )
Ranked among companies with meaningful Quick Ratio only.
CLSN' s Quick Ratio Range Over the Past 10 Years
Min: 0.3  Med: 3.81 Max: 104.65
Current: 1.44
0.3
104.65

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -41.20
CLSN's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CLSN: -41.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLSN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -66.2  Med: -27.8 Max: 1.9
Current: -41.2
-66.2
1.9

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.84
CLSN's Price/Median PS Value is ranked lower than
87% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. CLSN: 2.84 )
Ranked among companies with meaningful Price/Median PS Value only.
CLSN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 4.43 Max: 4324.13
Current: 2.84
0.13
4324.13
Earnings Yield (Greenblatt) (%) -87.99
CLSN's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CLSN: -87.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLSN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -87.99  Med: 715.7 Max: 887.9
Current: -87.99
-87.99
887.9

More Statistics

Revenue (TTM) (Mil) $0.50
EPS (TTM) $ -0.86
Beta1.75
Short Percentage of Float2.27%
52-Week Range $1.04 - 2.31
Shares Outstanding (Mil)25.81

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1 0 0 0
EPS ($) -0.88 -0.60 -0.54 -0.44
EPS w/o NRI ($) -0.88 -0.60 -0.54 -0.44
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CLSN

Headlines

Articles On GuruFocus.com
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 6,000 Shares Nov 19 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 5,000 Shares Aug 17 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 3,750 Shares Mar 18 2009 

More From Other Websites
Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer Sep 15 2016
ETF’s with exposure to Celsion Corp. : September 12, 2016 Sep 12 2016
Celsion Corporation Announces Independent NIH Analysis Showing Treatment with ThermoDox® Plus RFA... Sep 12 2016
CELSION CORP Files SEC form 8-K, Change in Directors or Principal Officers Sep 08 2016
Celsion Corporation to Present at Upcoming Investor Conferences Sep 07 2016
ETF’s with exposure to Celsion Corp. : August 30, 2016 Aug 30 2016
CELSION CORP Financials Aug 24 2016
Celsion Corporation to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August... Aug 22 2016
ETF’s with exposure to Celsion Corp. : August 19, 2016 Aug 19 2016
Celsion Corp. :CLSN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 Aug 18 2016
Celsion Corporation Reports Second Quarter 2016 Financial Results and Provides Business Update Aug 15 2016
CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 15 2016
Celsion Corporation Reports Second Quarter 2016 Financial Results and Provides Business Update Aug 15 2016
Celsion Corporation Announces Final Overall Survival Data from HEAT Study of ThermoDox® in Primary... Aug 15 2016
Celsion Corporation Announces Final Overall Survival Data from HEAT Study of ThermoDox® in Primary... Aug 15 2016
Q2 2016 Celsion Corp Earnings Release - Time Not Supplied Aug 15 2016
Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Sign Technology Transfer,... Aug 09 2016
Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Sign Technology Transfer,... Aug 09 2016
Celsion Corporation to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August... Aug 08 2016
Celsion Corporation to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August... Aug 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)